Mei Ri Jing Ji Xin Wen·2025-12-15 12:33Core Viewpoint - Fosun Pharma announced a plan to acquire a controlling stake in Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. for approximately 1.412 billion yuan to enhance its product pipeline in the central nervous system treatment sector [1] Group 1: Acquisition Details - The acquisition will result in Green Valley being included in Fosun Pharma's consolidated financial statements [1] - The main product of Green Valley is the sodium mannitol capsule (trade name: Jiuyi), which is used for treating Alzheimer's disease [1] Group 2: Regulatory and Clinical Trial Status - The sodium mannitol capsule has not been commercially produced since November 2024 due to the expiration of its registration approval [1] - Before resuming commercial production and sales, the product must complete post-marketing confirmatory clinical trials and obtain approval from the national drug regulatory authority [1] - Fosun Pharma plans to continue advancing the post-marketing confirmatory clinical trials to expedite the approval process [1]